                         SEQUENCE LISTING

<110>  LYELL IMMUNOPHARMA, INC.
 
<120>  METHODS FOR CULTURING IMMUNE CELLS

<130>  4385.043PC07

<150>  US 63/273,138
<151>  2021-10-28

<150>  US 63/181,218
<151>  2021-04-28

<150>  US 63/167,592
<151>  2021-03-29

<150>  US 63/165,023
<151>  2021-03-23

<150>  US 63/153,922
<151>  2021-02-25

<150>  US 63/146,477
<151>  2021-02-05

<150>  US 63/198,933
<151>  2020-11-23

<160>  7     

<170>  PatentIn version 3.5

<210>  1
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  KRAS Peptide Sequence

<400>  1

Cys Ala Ser Ser Leu Gly Thr Asp Thr Gln Tyr Phe 
1               5                   10          


<210>  2
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  KRAS Peptide Sequence

<400>  2

Cys Ala Ser Ser Arg Gly Leu Gly Asn Thr Ile Tyr Phe 
1               5                   10              


<210>  3
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  KRAS Peptide Sequence

<400>  3

Cys Ala Ser Ser Gln Asn Tyr Gly Tyr Thr Phe 
1               5                   10      


<210>  4
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  KRAS Peptide Sequence

<400>  4

Cys Ala Ser Ser Leu Val Gly Thr Glu Ala Phe Phe 
1               5                   10          


<210>  5
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  KRAS Peptide Sequence

<400>  5

Cys Ala Ser Ser Leu Arg Gly Thr Glu Ala Phe Phe 
1               5                   10          


<210>  6
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  KRAS Peptide Sequence

<400>  6

Cys Ala Ser Ser Gly Asp Ser Tyr Gly Tyr Thr Phe 
1               5                   10          


<210>  7
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  KRAS Peptide Sequence

<400>  7

Cys Ala Ser Gly Glu Thr Gln Tyr Phe 
1               5                   


